Reading this on a mobile device? Try our optimized mobile version here:

July 23, 2012
Sign upForwardArchive
News for the PBM Industry

  Legislative & Regulatory News 
  • PCMA: Protected drug classes will drive up health costs
    Pharmacy benefit managers are fighting a proposal to mandate that health insurers cover drugs in six "protected" classes, as is required under Medicare Part D. "These 'protected class' mandates would grant drug companies unlimited pricing power and make coverage less affordable for individuals and small businesses," Pharmaceutical Care Management Association President and CEO Mark Merritt said. "Small businesses shouldn't have to choose between a bloated Cadillac plan and no plan at all. They want access to affordable plans that offer broad coverage, promote generics and reduce brand name drug costs." (subscription required) (7/23) LinkedInFacebookTwitterEmail this Story
  • Study: Many adults on Medicaid do not stick to Rx
    About 37% of adult Medicaid recipients with diabetes, high cholesterol and high blood pressure do not take their medications as prescribed, a study of more than 150,000 Medicaid patients found. Giving once-a-day or combination doses, using pill boxes and dispensing in 90-day instead of 30-day quantities could improve adherence, the lead researcher said. HealthDay News (7/20) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Fake Avastin may have reached U.S. via Canadian company
    Counterfeit batches of cancer drug Avastin may have entered the U.S. via Canada Drugs, which sells drugs to U.S. consumers through its Internet pharmacy, a Wall Street Journal investigative report found. Other parts of the company sell to U.S. doctors. After big drugmakers looking to protect profits dropped online pharmacies from the Canadian supply chain, the company turned to buying drugs from countries with regulatory or enforcement problems, though the owner implemented procedures to avoid purchasing counterfeit drugs. The Wall Street Journal (7/20) LinkedInFacebookTwitterEmail this Story
  • Niche may help small generic-drug-makers survive price competition
    Smaller generic-drug-makers' best hope of surviving price competition might be finding a specialization. Smaller companies are feeling pressure from aggressive consolidation among European and U.S. generics makers. Niche therapeutics might save small firms from price reduction if they select a market with high entry barriers, such as psychiatric disorders, women's health care and injectable drugs. Reuters (7/20) LinkedInFacebookTwitterEmail this Story
Never interrupt someone doing what you said couldn't be done."
--Amelia Earhart,
American aviator


Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information